Moderna (MRNA) investor relations material

Strategic vision, platform innovation, and growth plans

• Multi-horizon strategy spans established, clinical-stage, and future modalities, with a robust pipeline in infectious disease, oncology, autoimmune, and rare diseases.

• AI and automation, including the Lucy Scientific Intelligence Engine, are central to accelerating discovery, data integration, and iterative learning cycles.

• mRED (Moderna Research and Early Development) structure enables rapid, data-driven decision-making and advances new modalities from idea to clinical proof-of-concept.

• Multiplexing technology and T-cell engagers allow encoding multiple proteins or antibodies in a single mRNA product, enhancing efficacy and de-risking follow-on programs.

• Global expansion through partnerships and new approvals in the UK, Canada, Australia, LATAM, APAC, EU, Japan, Switzerland, and Taiwan supports growth.

Pipeline highlights, clinical progress, and innovation

• Infectious disease vaccines (COVID-19, RSV, flu) are approved or filed; norovirus is in Phase 3, with launches expected to drive near-term growth.

• Oncology programs include intismeran in multiple Phase 2/3 trials and mRNA-4359, which shows promising efficacy and safety in melanoma and NSCLC.

• Cancer antigen therapies (mRNA-4106, 4200, 4194), T-cell engagers (mRNA-2808, 2151), and cell therapy enhancers are advancing through clinical stages.

• EBV therapeutic vaccine (mRNA-1195) for MS demonstrates strong immunogenicity, sustained antibody and T-cell responses, and reduced viral shedding.

• In vivo CAR-T (mRNA-6007/007) for autoimmune diseases shows preclinical proof of concept for scalable, off-the-shelf immune reset, with clinical entry planned for 2027.

Financial guidance, commercialization, and future outlook

• Targets up to 10% revenue growth in 2026, driven by vaccine launches, oncology, and rare disease therapeutics, with cash breakeven expected by 2028.

• 2026 adjusted cash cost target is $4.2B, inclusive of mRED investments.

• Commercial strategy remains flexible, with decisions on internal development or partnerships made post-human proof-of-concept.

• Near-term catalysts include product launches, regulatory milestones, and key clinical data readouts for oncology and rare disease programs.

• Leadership emphasizes commitment to learning faster, scaling innovation, and realizing the full potential of mRNA medicines.